NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine

Shares of Novavax (NVAX) surged nearly 26% in pre-market trading today after its protein-based COVID-19 vaccine, Nuvaxovid, received the long-awaited approval from the FDA, albeit with a narrower label than initially expected.FDA’s Conditions on NVAX’s COVID-19 JabWhile the agency granted full approval to Nuvaxovid for use in older adults aged 65 and above, it restricted the vaccine’s use in individuals aged 12-64 with at least one underlying condition that puts them at high risk for severe outcomes from CO ...